|25.66||-1.98||-7.16%||Vol 749.37K||1Y Perf -26.25%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||44.73||Analyst Rating||Moderate Buy 1.63|
|Potential %||74.32||Finscreener Ranking||★★★+ — -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★+ 57.76|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★ — -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||20.87||Earnings Rating||Buy|
|Market Cap||3.65B||Earnings Date||3rd Nov 2021|
Today's Price Range
|Moving Averages:||Strong Buy|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Nov 2021|
|Estimated EPS Next Report||-0.55|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||851.30K|
|Avg. Monthly Volume||665.34K|
|Avg. Quarterly Volume||813.02K|
Allogene Therapeutics Inc. (NASDAQ: ALLO) stock closed at 25.66 per share at the end of the most recent trading day (a -7.16% change compared to the prior day closing price) with a volume of 749.67K shares and market capitalization of 3.65B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 265 people. Allogene Therapeutics Inc. CEO is David D. Chang.
The one-year performance of Allogene Therapeutics Inc. stock is -26.25%, while year-to-date (YTD) performance is 1.66%. ALLO stock has a five-year performance of %. Its 52-week range is between 20.58 and 44.92, which gives ALLO stock a 52-week price range ratio of 20.87%
Allogene Therapeutics Inc. currently has a PE ratio of -13.90, a price-to-book (PB) ratio of 3.52, a price-to-sale (PS) ratio of 92.15, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -20.02%, a ROC of -21.26% and a ROE of -21.83%. The company’s profit margin is -%, its EBITDA margin is -588.90%, and its revenue ttm is $38.39 Million , which makes it $0.27 revenue per share.
Of the last four earnings reports from Allogene Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Allogene Therapeutics Inc.’s next earnings report date is 03rd Nov 2021.
The consensus rating of Wall Street analysts for Allogene Therapeutics Inc. is Moderate Buy (1.63), with a target price of $44.73, which is +74.32% compared to the current price. The earnings rating for Allogene Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Allogene Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Allogene Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.55, ATR14 : 1.22, CCI20 : 141.86, Chaikin Money Flow : 0.12, MACD : 0.66, Money Flow Index : 67.43, ROC : 2.03, RSI : 55.09, STOCH (14,3) : 44.44, STOCH RSI : 0.13, UO : 55.00, Williams %R : -55.56), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Allogene Therapeutics Inc. in the last 12-months were: Alison Moore (Option Excercise at a value of $240 148), Alison Moore (Sold 130 576 shares of value $5 326 671 ), Arie S. Belldegrun (Option Excercise at a value of $6 906 582), David D. Chang (Option Excercise at a value of $499 410), David D. Chang (Sold 20 513 shares of value $791 271 ), Eric Schmidt (Option Excercise at a value of $271 423), Eric Schmidt (Sold 68 053 shares of value $2 353 897 ), Owen N. Witte (Sold 19 969 shares of value $493 623 ), Rafael Amado (Sold 19 336 shares of value $757 985 ), Veer Bhavnagri (Option Excercise at a value of $253 105), Veer Bhavnagri (Sold 66 623 shares of value $2 105 983 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.